dermatomyositis: Dermatomyositis (DM) is a type of idiopathic inflammatory myopathy characterized by evocative skin lesions and symmetrical proximal muscle weakness.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
191 |
4. Check minimum number of eventsNone |
191 |
5. Include endpointsNone |
191 |
6. Filter based on genotype QC (FinnGen only) |
183 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M33
- Name in latin
- Dermato[poly]myositis non specificata
Similar endpoints
↥List of similar endpoints to
Dermatopolymyositis, unspecified
based on the number of shared cases.
Similar with more cases:
- Dermatopolymyositis (FG)
- Dermatopolymyositis
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Finngen Rheumatological endpoints
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 919 | 568 | 346 |
| Only index persons | 811 | 503 | 308 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 59.15 | 58.28 | 60.73 |
| Only index persons | 57.73 | 56.78 | 59.29 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 183 | 107 | 76 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.03 |
| Median age at first event (years) | 57.28 | 53.98 | 61.91 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 191
- Matched controls
- 1910
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M33.9
ICD-10 Finland
Dermatopolymyositis, unspecified
+∞
267.4
188
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
19.1
95.8
102
108
M33.1
ICD-10 Finland
Other dermatomyositis
+∞
82.4
73
*
L04AX03
ATC
methotrexate; systemic
16.2
79.3
87
94
L04AX01
ATC
azathioprine; systemic
31.8
78.8
55
24
P01BA02
ATC
hydroxychloroquine; oral
16.0
71.9
75
74
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
16.2
54.5
52
43
M33.2
ICD-10 Finland
Polymyositis
+∞
45.7
42
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
8.4
44.3
139
462
M05BA04
ATC
alendronic acid; oral
10.1
39.5
52
68
H02AB06
ATC
prednisolone; systemic
9.8
39.2
160
660
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
9.9
37.6
50
66
M60.9
ICD-10 Finland
Myositis, unspecified
212.8
35.0
35
*
L04AA06
ATC
mycophenolic acid; systemic
53.2
29.9
35
8
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
341.1
29.6
29
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
9.3
27.8
37
48
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
104.3
25.4
27
*
J99.1*M33.9
ICD-10 Finland
Respiratory disorders in dermatopolymyositis
+∞
24.5
23
*
NXL00
NOMESCO Finland
Biopsy of muscle
142.9
24.2
25
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
6.2
23.5
47
95
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
74.7
23.5
26
*
G72.9
ICD-10 Finland
Myopathy, unspecified
40.7
22.8
28
8
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
6.9
22.0
38
66
M60.8
ICD-10 Finland
Other myositis
222.1
19.9
20
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.8
18.1
88
352
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.4
15.0
121
645
L04AD01
ATC
ciclosporin; systemic
22.1
14.1
20
10
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
+∞
13.7
13
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.3
13.2
67
267
ZX120
NOMESCO Finland
Intravenous
4.4
13.1
38
103
H02AB07
ATC
prednisone; oral
3.9
13.1
46
144
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.0
12.8
43
130
J99.1*M33.2
ICD-10 Finland
Respiratory disorders in polymyositis
+∞
11.6
11
*
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
37.5
11.4
14
*
L01BA01
ATC
methotrexate; systemic
10.6
11.1
21
22
L04AA01
ATC
[U] ciclosporin
30.0
10.9
14
5
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
13.1
10.6
18
15
M35.1
ICD-10 Finland
Other overlap syndromes
+∞
10.5
10
*
M33
ICD-10 Finland
Dermatopolymyositis
+∞
10.5
10
*
M33.0
ICD-10 Finland
Juvenile dermatomyositis
+∞
10.5
10
*
XG410
NOMESCO Finland
Flow-volume spirometry
8.9
10.1
21
26
HA1AA
NOMESCO Finland
X-ray mammography
4.0
9.4
29
82
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
4.3
9.3
26
68
D07AC01
ATC
betamethasone; topical
2.6
9.1
86
463
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
8.7
9.1
19
24
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
25.4
9.0
12
5
D07AB08
ATC
desonide; topical
3.4
9.0
37
127
A02BC02
ATC
pantoprazole; systemic
2.9
9.0
149
1047
Z09.0
ICD-10 Finland
Follow-up examination after surgery for other conditions
4.2
8.5
24
63
XA402
NOMESCO Finland
ENMG
9.2
8.5
17
20
1XC02, ,
NOMESCO Finland
94.0
8.5
9
*
J99.1
ICD-10 Finland
Respiratory disorders in other diffuse connective tissue disorders
+∞
8.4
8
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
4.1
8.4
24
64
JN4BD
NOMESCO Finland
Extensive body CT
3.3
8.2
34
117
M05BA07
ATC
risedronic acid; oral
7.8
8.2
18
25
L28
ICPC
Limited function/disability (L)
2.9
8.1
46
190
R50.9
ICD-10 Finland
Fever, unspecified
3.0
7.7
40
157
C03CA01
ATC
furosemide; systemic
2.5
7.5
67
345
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
11.5
7.4
13
12
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.6
7.4
51
233
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.2
7.3
31
108
E0000UV, ,
ATC
2.3
7.2
94
569
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
31.3
7.2
9
*
R2110
NOMESCO Finland
Giving the first information
4.3
7.1
19
48
TPH04
NOMESCO Finland
Cathetrisation of vein
2.5
7.0
55
266
SPAT1229
SPAT
Assessment of need for aid
3.9
7.0
21
58
R06.0
ICD-10 Finland
Dyspnoea
2.4
6.9
62
319
L99
ICPC
Musculoskeletal disease other
8.3
6.7
14
18
L29
ICPC
Musculoskeletal sympt/complt other
3.4
6.7
25
80
M35.3
ICD-10 Finland
Polymyalgia rheumatica
9.2
6.7
13
15
L88
ICPC
Rheumatoid/seropositive arthritis
6.1
6.6
17
30
E000001, ,
ATC
2.5
6.5
48
225
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
11.6
6.4
11
10
NJ3DG
NOMESCO Finland
Very extensive MRI examination of extremities with high intensity magnet
+∞
6.3
6
*
XPX04
NOMESCO Finland
Angioscopy
+∞
6.3
6
*
N03AX16
ATC
[U] pregabalin
2.3
6.2
56
287
R13
ICD-10 Finland
Dysphagia
3.5
6.2
22
68
M05BX04
ATC
denosumab; parenteral
3.9
6.2
19
53
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
67
6
170.27
66.98
3.9
1.2
6.44
5.60
u/l
—
62
6
63
5
186.46
63.34
1.3
1.0
—
—
—
0
0
154
455
13.31
59.83
13.3
1.9
195.92
186.56
u/l
0.11
154
426
52
42
16.64
55.29
2.4
1.3
—
—
—
0
0
46
40
14.83
46.49
1.8
1.1
0.21
0.25
g/l
1.81
46
40
46
43
13.77
44.39
1.8
1.0
1.11
1.26
g/l
2.31
46
43
36
42
10.33
29.39
1.6
1.4
330.28
0.08
iu/ml
—
10
9
161
915
5.84
20.75
19.3
9.5
4.25
4.07
e9/l
0.51
156
804
131
766
3.26
13.23
5.2
3.5
0.00
0.00
estimate
-0.00
37
160
132
781
3.23
12.95
5.3
3.4
0.00
0.00
estimate
-0.00
36
147
130
773
3.13
12.44
6.5
4.6
0.00
0.00
estimate
-0.00
36
152
114
638
2.95
12.05
3.4
2.2
72.91
77.20
nmol/l
0.94
109
570
43
136
3.79
12.00
2.0
1.9
392.02
358.88
nmol/l
0.14
43
124
128
768
3.02
11.80
10.4
6.5
1.22
1.21
mmol/l
0.41
111
659
24
49
5.46
11.56
4.0
3.0
—
—
—
0
0
51
196
3.19
10.41
3.0
2.1
24.38
23.26
%
0.19
46
176
16
11
15.74
10.20
1.6
1.1
—
—
—
0
0
16
11
15.74
10.20
1.6
1.1
—
—
—
0
0
16
12
14.42
9.86
1.6
1.1
—
—
—
0
0
16
12
14.42
9.86
1.6
1.1
—
—
—
0
0
16
12
14.42
9.86
1.6
1.1
—
—
—
0
0
75
370
2.69
9.59
3.1
1.9
3.23
3.01
mg/l
0.40
68
318
55
231
2.94
9.55
3.1
2.0
13.60
13.53
umol/l
0.02
55
215
60
266
2.83
9.41
1.4
1.2
62.42
40.56
iu/ml
0.37
16
88
51
211
2.93
9.05
3.1
2.0
2.28
2.35
g/l
0.41
51
191
18
22
8.91
8.80
4.6
2.6
61.61
63.59
%
0.21
18
22
19
41
5.04
8.56
6.5
3.0
0.00
0.00
g/l
-0.00
19
41
52
225
2.80
8.45
2.3
1.8
—
—
—
0
0
17
21
8.77
8.29
4.3
1.8
4.37
5.85
e9/l
0.98
17
21
18
39
4.99
8.06
6.8
3.1
0.00
0.00
g/l
-0.00
18
39
18
39
4.99
8.06
6.8
3.1
0.00
0.00
g/l
-0.00
18
39
14
13
11.51
7.94
1.5
1.2
—
—
—
0
0
77
421
2.39
7.60
6.3
3.9
0.00
0.00
estimate
-0.00
36
147
79
442
2.34
7.35
5.7
3.0
845.64
1099.30
ng/l
0.67
74
371
10
5
20.98
7.21
1.7
1.6
—
—
—
0
0
13
15
9.21
6.67
1.3
1.1
23.33
68.40
%
—
6
10
20
57
3.80
6.35
6.3
2.4
—
—
—
0
0
52
260
2.37
6.10
1.2
1.2
33.16
9.06
u/ml
0.59
16
98
17
34
5.38
6.04
1.6
1.3
—
—
—
0
0
36
155
2.63
5.77
1.9
1.7
—
—
—
0
0
19
56
3.66
5.75
1.6
1.5
1.17
1.63
g/l
2.03
19
48
16
32
5.36
5.71
1.3
1.6
—
—
—
0
0
9
7
13.41
5.64
1.8
5.3
—
—
—
0
0
92
598
2.04
5.48
5.8
3.6
—
—
—
0
0
88
567
2.02
5.33
4.5
2.9
—
—
—
0
0
10
12
8.72
5.12
1.6
1.1
—
—
—
0
0
62
356
2.10
5.10
1.4
1.2
0.80
1.77
u/ml
0.88
13
99
12
22
5.74
4.68
1.2
1.1
—
—
—
0
0
34
158
2.40
4.62
2.1
1.7
—
—
—
0
0
52
291
2.08
4.52
2.0
1.6
1233.44
1191.73
nmol/l
0.12
44
223
21
77
2.94
4.52
1.8
1.8
—
—
—
0
0
80
533
1.86
4.14
2.4
3.4
2.32
2.36
mmol/l
1.40
74
466
12
26
4.85
4.13
1.7
1.7
—
—
—
0
0
61
373
1.93
4.10
1.8
1.4
17.73
21.58
nmol/l
1.73
53
313
14
36
4.11
4.09
1.6
1.6
—
—
—
0
0
9
14
6.68
4.03
2.0
1.4
2.57
4.08
mg/l
—
9
14
14
43
3.43
3.99
1.2
1.1
—
—
—
0
0
12
28
4.50
3.89
1.3
1.4
—
—
—
0
0
10
19
5.49
3.88
1.5
1.6
—
—
—
0
0
11
24
4.80
3.81
1.2
1.3
3.40
13.00
u/ml
—
5
6
64
408
1.86
3.74
4.2
2.8
6431.81
9150.51
umol/l
0.16
58
351
100
731
1.77
3.70
18.7
11.8
1.25
1.24
inr
0.04
33
220
69
456
1.80
3.57
4.0
2.9
0.16
0.41
e6/l
1.61
58
338
46
268
1.94
3.51
3.5
2.6
0.75
0.94
e6/l
0.34
31
147
10
22
4.74
3.48
1.5
1.6
—
—
—
0
0
13
37
3.69
3.48
1.7
1.6
—
—
—
0
0
9
18
5.19
3.41
1.8
1.4
—
—
—
0
0
25
120
2.25
3.15
4.0
4.4
1.22
1.22
mmol/l
0.23
25
108
11
30
3.83
3.14
1.5
1.6
—
—
—
0
0
10
25
4.16
3.13
1.2
1.3
—
—
—
0
0
71
491
1.71
3.06
2.9
2.2
54.74
64.42
u/l
0.49
66
455
7
12
6.01
3.05
1.0
1.1
—
—
—
0
0
31
166
2.04
2.98
6.5
7.6
1.26
1.47
mmol/l
0.10
25
133
83
605
1.66
2.90
6.2
3.5
79.56
38.39
ng/l
0.72
77
410
7
13
5.54
2.89
1.1
1.0
—
—
—
0
0
9
23
4.05
2.81
1.9
1.7
—
—
—
0
0
7
14
5.14
2.75
1.7
1.6
—
—
—
0
0
8
20
4.13
2.60
1.8
2.1
—
—
—
0
0
5
7
7.29
2.56
1.4
1.0
—
—
—
0
0
5
7
7.29
2.56
1.4
1.0
—
—
—
0
0
6
11
5.59
2.56
1.0
1.2
—
—
—
0
0
5
9
5.67
2.22
1.0
1.2
—
—
—
0
0
39
249
1.71
2.18
3.9
2.8
5.44
2.02
e6/l
1.05
24
130
6
14
4.39
2.17
1.8
1.5
—
—
—
0
0
6
14
4.39
2.17
1.2
1.3
—
—
—
0
0
6
14
4.39
2.17
1.8
1.5
—
—
—
0
0
6
15
4.09
2.05
1.0
1.1
—
—
—
0
0
8
26
3.17
2.04
1.6
1.7
—
—
—
0
0
8
26
3.17
2.04
1.6
1.7
—
—
—
0
0
10
38
2.72
2.03
1.0
1.1
—
20.26
—
0
5
19
99
2.02
1.98
1.5
1.5
—
—
—
0
0
7
21
3.42
1.98
1.6
1.2
—
—
—
0
0
5
11
4.63
1.95
1.8
1.5
—
—
—
0
0
6
16
3.83
1.95
2.2
1.4
—
—
—
0
0
6
150
0.38
1.86
1.2
1.8
—
—
—
0
0
142
1565
0.64
1.86
5.3
4.5
5.76
5.95
mmol/l
1.41
135
1430
28
171
1.75
1.83
2.5
4.7
3.05
32.52
ug/l
0.66
22
146
5
13
3.92
1.72
1.2
1.2
—
—
—
0
0
62
467
1.49
1.72
4.0
3.7
4.13
9.08
mg/mmol
1.69
40
286
12
56
2.22
1.65
3.1
2.1
—
—
—
0
0
5
14
3.64
1.62
1.4
1.4
—
—
—
0
0
6
20
3.06
1.59
1.3
1.8
—
—
—
0
0
11
51
2.23
1.53
1.2
1.4
—
—
—
0
0
5
15
3.39
1.53
1.4
2.0
—
—
—
0
0
5
15
3.39
1.53
1.4
2.0
—
—
—
0
0
5
15
3.39
1.53
1.4
2.0
—
—
—
0
0
6
21
2.92
1.52
1.3
1.7
—
—
—
0
0
7
28
2.56
1.46
2.6
1.3
—
—
—
0
0
7
28
2.56
1.46
1.1
1.1
—
—
—
0
0
14
74
1.96
1.43
1.6
1.3
—
—
—
0
0
9
41
2.25
1.39
1.0
1.5
—
—
—
0
0
25
163
1.61
1.31
3.5
3.7
—
—
—
0
0
10
49
2.10
1.24
2.9
1.8
—
—
—
0
0
171
1605
1.62
1.24
32.6
13.0
17.37
23.00
mg/l
2.39
157
1248
8
37
2.21
1.23
2.5
2.2
25.69
25.70
mmol/l
—
8
37
5
19
2.67
1.22
1.0
1.1
—
3.31
—
0
8
136
1226
1.38
1.20
5.3
3.9
14.93
14.71
pmol/l
0.46
130
1103
8
38
2.15
1.20
1.1
1.2
—
—
—
0
0
6
26
2.35
1.19
1.3
1.3
—
—
—
0
0
6
26
2.35
1.19
1.3
1.3
—
—
—
0
0
143
1542
0.71
1.19
4.8
4.0
1.63
1.27
mmol/l
3.36
135
1411
77
639
1.34
1.17
2.7
1.8
95.08
96.05
pmol/l
0.07
46
324
10
51
2.01
1.13
2.2
1.6
—
—
—
0
0
150
1601
0.71
1.11
5.2
4.5
4.82
4.70
mmol/l
0.84
143
1476
7
31
2.30
1.11
1.9
1.4
—
—
—
0
0
35
256
1.45
1.11
1.3
1.4
—
—
—
0
0
149
1592
0.71
1.11
5.1
4.5
1.41
1.49
mmol/l
1.45
141
1463
89
760
1.32
1.10
3.6
2.5
—
—
—
0
0
39
293
1.42
1.08
5.9
3.5
324.63
285.95
ng/l
0.08
30
227
7
35
2.04
1.01
3.1
1.4
—
—
—
0
0
39
299
1.38
0.96
2.2
3.0
2.48
2.45
mmol/l
0.60
34
263
45
356
1.35
0.92
2.0
1.7
1.44
1.18
mg/l
0.34
31
277
33
248
1.40
0.92
2.7
1.9
29.46
29.21
s
0.07
33
241
155
1633
0.73
0.88
5.4
5.0
2.88
2.79
mmol/l
0.66
147
1503
14
88
1.64
0.87
1.2
1.2
218.40
142.50
u/ml
0.16
14
82
8
45
1.81
0.85
1.1
1.2
—
—
—
0
0
8
45
1.81
0.85
1.0
1.4
—
333.86
—
0
26
8
46
1.77
0.83
1.1
1.2
—
—
—
0
0
15
98
1.58
0.81
1.3
1.2
113.72
123.62
iu/ml
—
5
43
14
91
1.58
0.77
15.6
6.4
25.88
24.88
mmol/l
0.57
14
91
0
22
0.00
0.59
0.0
1.0
—
—
—
0
0
161
1543
1.28
0.56
25.2
12.6
83.29
81.71
ml/min/173m2
0.32
144
1261
46
391
1.23
0.55
2.6
2.3
—
—
—
0
0
18
134
1.38
0.55
4.5
3.6
6.12
5.73
kpa
0.68
18
128
6
39
1.56
0.53
1.2
1.1
399.50
443.18
mg/l
—
6
39
24
190
1.30
0.51
1.5
1.8
1.75
1.42
%
2.36
17
165
146
1524
0.82
0.50
7.4
5.5
40.72
39.84
mmol/mol
0.58
141
1415
10
69
1.47
0.45
5.8
3.6
57.00
47.34
%
—
10
69
155
1491
1.21
0.43
6.1
4.7
1.97
1.89
mu/l
0.36
147
1350
0
15
0.00
0.41
0.0
1.0
—
440.70
—
0
10
0
15
0.00
0.41
0.0
2.1
—
13.45
—
0
15
0
15
0.00
0.41
0.0
1.0
—
39.78
—
0
9
36
414
0.84
0.38
3.6
4.5
22.18
21.25
%
0.16
17
211
10
72
1.41
0.37
4.1
2.3
0.64
0.62
%
—
10
72
116
1101
1.14
0.34
4.4
2.8
73.96
47.51
u/l
1.58
110
1036
175
1712
1.26
0.34
34.7
15.6
75.91
76.94
umol/l
0.11
175
1712
6
47
1.29
0.32
1.3
1.5
—
—
—
0
0
95
1006
0.89
0.31
3.1
2.9
—
—
—
0
0
17
139
1.24
0.30
3.4
2.1
56.43
65.25
ml/min/173m2
—
7
57
12
151
0.78
0.29
3.6
1.8
—
—
—
0
0
10
76
1.33
0.28
4.1
2.3
1.65
1.19
%
—
10
76
9
73
1.24
0.26
2.9
1.9
—
—
—
0
0
22
189
1.19
0.25
9.7
6.9
103.18
103.92
mmol/l
0.28
22
189
10
79
1.28
0.23
1.2
1.3
—
—
—
0
0
28
313
0.88
0.22
2.8
3.0
0.68
0.76
ug/l
0.42
17
214
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
9.57
—
0
12
0
12
0.00
0.21
0.0
2.9
—
—
—
0
0
0
12
0.00
0.21
0.0
2.9
—
—
—
0
0
14
117
1.21
0.21
4.4
2.7
4.56
4.38
kpa
0.15
14
110
177
1793
0.82
0.21
43.5
19.5
39.50
40.35
%
1.26
165
1695
25
280
0.88
0.20
1.7
1.5
—
—
—
0
0
7
61
1.15
0.17
3.0
1.8
—
—
—
0
0
8
78
1.03
0.07
1.0
1.0
—
—
—
0
0
46
446
1.04
0.05
1.7
1.6
1.86
1.35
mmol/l
1.85
39
375
166
1667
0.97
0.01
28.5
15.1
3.94
3.97
mmol/l
0.94
161
1617
52
514
1.02
0.00
4.7
5.1
3.13
2.84
ug/l
0.07
47
460
17
169
1.01
0.00
3.1
1.9
—
—
—
0
0
166
1661
1.00
0.00
27.9
15.0
139.41
139.78
mmol/l
1.22
161
1613
21
212
0.99
0.00
9.3
5.9
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
6
0.00
-0.00
0.0
1.0
—
118.33
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
112.00
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
7
0.00
-0.00
0.0
2.6
—
114.43
—
0
7
Mortality – FinRegistry
↥Association
Association between endpoint M13_DERMATOPOLYNAS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_DERMATOPOLYNAS | 2.848 [2.14, 3.79] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.207 |
During the follow-up period (1.1.1998 — 31.12.2019), 130 out of 495 females with M13_DERMATOPOLYNAS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_DERMATOPOLYNAS | 2.483 [1.74, 3.55] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.017 |
During the follow-up period (1.1.1998 — 31.12.2019), 87 out of 295 males with M13_DERMATOPOLYNAS died.
Mortality risk
Mortality risk for people of age
years, who have M13_DERMATOPOLYNAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.296% | 0.595% |
| 5 | 1.603% | 3.498% |
| 10 | 4.077% | 7.608% |
| 15 | 7.333% | 14.038% |
| 20 | 12.719% | 22.408% |
Relationships between endpoints
↥Index endpoint: M13_DERMATOPOLYNAS – Dermatopolymyositis, unspecified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data